USD 9.59
(1.48%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 8.06 Billion USD | -1.71% |
2022 | 8.2 Billion USD | -2.26% |
2021 | 8.39 Billion USD | 1890.41% |
2020 | -469 Million USD | -118.14% |
2019 | -215 Million USD | -126.32% |
2018 | -95 Million USD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | 8.13 Billion USD | 0.89% |
2024 Q3 | 7.98 Million USD | 0.43% |
2024 Q2 | 7.95 Billion USD | -2.3% |
2023 Q1 | 8.25 Billion USD | 0.55% |
2023 FY | 8.06 Billion USD | -1.71% |
2023 Q4 | 8.06 Billion USD | -2.1% |
2023 Q3 | 8.24 Billion USD | -1.95% |
2023 Q2 | 8.4 Billion USD | 1.84% |
2022 Q3 | 8.2 Billion USD | -1.77% |
2022 Q2 | 8.34 Billion USD | -0.62% |
2022 Q1 | 8.4 Billion USD | 0.04% |
2022 FY | 8.2 Billion USD | -2.26% |
2022 Q4 | 8.2 Billion USD | 0.09% |
2021 Q3 | 8.29 Billion USD | -3.81% |
2021 Q2 | 8.61 Billion USD | 524.95% |
2021 FY | 8.39 Billion USD | 1890.41% |
2021 Q1 | 1.37 Billion USD | 64.36% |
2021 Q4 | 8.39 Billion USD | 1.29% |
2020 Q4 | 839 Million USD | 0.0% |
2020 FY | -469 Million USD | -118.14% |
2020 Q1 | 319 Million USD | 0.0% |
2019 FY | -215 Million USD | -126.32% |
2018 FY | -95 Million USD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
AbbVie Inc. | 46.57 Billion USD | 82.678% |
Bristol-Myers Squibb Company | 30 Billion USD | 73.11% |
Bristol-Myers Squibb Company Ce | 30 Billion USD | 73.11% |
Johnson & Johnson | 7.47 Billion USD | -7.949% |
Eli Lilly and Company | 22.4 Billion USD | 63.997% |
Merck & Co., Inc. | 29.35 Billion USD | 72.523% |
Novartis AG | 12.95 Billion USD | 37.731% |
Pfizer Inc. | 72.18 Billion USD | 88.825% |